STK32A and differentiated thyroid carcinoma: In 2021, Yang et al. first reported that LOC339059 was down-regulated and had remarkable diagnostic value for papillary thyroid carcinoma (PTC) patients and predicted the crucial role of LOC339059-STK32A-hsa-miR-199b-5p in PTC based on the analysis of RNA sequencing data from The Cancer Genome Atlas (TCGA) database [23].